SYN-004 (ribaxamase), an oral β-lactamase designed to protect the gut microbiome from the deleterious effects of certain intravenously administered β-lactam antibiotics, degrades ceftriaxone excreted into the intestine in Phase 2a clinical studies.

Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis. Antimicrob Agents Chemother (2017) 0.75

Diversity of the human intestinal microbial flora. Science (2005) 49.64

Diversity, stability and resilience of the human gut microbiota. Nature (2012) 9.09

Three decades of beta-lactamase inhibitors. Clin Microbiol Rev (2010) 5.54

Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol (2005) 5.35

Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol (2014) 2.49

Gut microbiome-host interactions in health and disease. Genome Med (2011) 2.48

Country-specific antibiotic use practices impact the human gut resistome. Genome Res (2013) 1.94

Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis (2011) 1.85

Beta-lactam antibiotics: from antibiosis to resistance and bacteriology. APMIS (2010) 1.78

Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology (2014) 1.77

The re-emerging role of the intestinal microflora in critical illness and inflammation: why the gut hypothesis of sepsis syndrome will not go away. J Leukoc Biol (2007) 1.39

Effects of intestinal microflora and the environment on the development of asthma and allergy. Springer Semin Immunopathol (2003) 1.35

Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections. Am J Med (1984) 1.34

Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf (2006) 1.32

Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy. Eur J Clin Pharmacol (1986) 1.12

The human gut resistome. Philos Trans R Soc Lond B Biol Sci (2015) 1.10

Therapy and epidemiology of autism--clostridial spores as key elements. Med Hypotheses (2007) 1.04

Clostridium difficile infection. Nat Rev Dis Prim (2016) 0.99

Enzymic degradation of a beta-lactam antibiotic, ampicillin, in the gut: a novel treatment modality. J Antimicrob Chemother (2003) 0.99

Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti Infect Ther (2014) 0.97

Interactions Between the Gastrointestinal Microbiome and Clostridium difficile. Annu Rev Microbiol (2015) 0.93

P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin. Antimicrob Agents Chemother (2009) 0.91

Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile. J Antimicrob Chemother (2008) 0.87

Effects of β-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea. PLoS One (2014) 0.86

Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond. Urol Clin North Am (2015) 0.85

Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance. Genes (Basel) (2015) 0.84

Orally administered targeted recombinant Beta-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing antimicrobial resistance. Antimicrob Agents Chemother (2004) 0.84

IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora. Curr Opin Investig Drugs (2009) 0.83

Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. J Infect (2016) 0.83

Biliary excretion of antimicrobial drugs. Chemotherapy (2002) 0.82

Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Anaerobe (2016) 0.80

Vancomycin-resistant Clostridium innocuum bacteremia following oral vancomycin for Clostridium difficile infection. Anaerobe (2014) 0.79

The environment within: exploring the role of the gut microbiome in health and disease. Environ Health Perspect (2013) 0.79

Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics. Int J Toxicol (2015) 0.78

Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harm. Infect Drug Resist (2015) 0.77

Biliary excretion of amoxycillin and ceftriaxone after intravenous administration in man. Br J Clin Pharmacol (1982) 0.77

Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies. Clin Drug Investig (2016) 0.76